To determine whether inhibiting the biosynthesis of GSLs with GluCer synthase inhibitors can prevent the mTOR/α-synuclein alterations caused by GCase deficiency, we treated GBA1/PD–DA neurons with IBI for the last 10 days of dopaminergic differentiation. The gene discussed is GBA1; the disease is Parkinson disease.